Featured Research

from universities, journals, and other organizations

Snipping Inflammation In The Bud; New Agents May Provide Relief

Date:
March 5, 1998
Source:
University Of Wisconsin-Madison
Summary:
Trying a new approach to controlling the process of inflammation, scientists have forged a new class of synthetic molecules that offer a new strategy for treating pain, swelling and the other hallmarks of injury or illness.

MADISON - Trying a new approach to controlling the process of inflammation, scientists have forged a new class of synthetic molecules that offer a new strategy for treating pain, swelling and the other hallmarks of injury or illness.

Writing this week (March 5) in the scientific journal Nature, University of Wisconsin-Madison chemist Laura L. Kiessling describes a new family of compounds that packs a novel one-two punch that effectively inhibits the cellular processes that cause us pain.

Inflammation is the body's response to irritation, infection or injury. It begins at the level of the cell when, in response to an injury or irritation, white blood cells in the bloodstream begin to stick to the cells lining the blood vessel wall. The end result of this process is inflammation and pain.

The cells stick together with the aid of a protein called L-selectin that, with many other proteins, populates the surface of cells.

"L-selectin helps mediate an inflammatory response by binding to the carbohydrate groups attached to protein molecules on the surface of an opposing cell," said Kiessling. "The many copies of L-selectin on the white blood cell surface bind with the many copies of the L-selectin-binding protein on the blood vessel, much like fingers fitting into a glove. The inflammatory response depends on the cells sticking together."

The traditional approach to controlling inflammation, through popular over-the-counter drugs such as ibuprofen, is to block events inside the cell. The synthetic molecules in Kiessling's approach act as inhibitors on the outside of the cell, attaching themselves to a L-selectin proteins and preventing the cell from linking with an opposing cell.

But synthetic molecules that only inhibit cells from linking up have to compete with the natural cell surface proteins involved in the cell-docking process, and they don't always win. The process is also reversible. The synthetic molecules, for example, can slip off their cellular targets and the L-selectin proteins can come back into play.

However, the new class of agents developed by Kiessling and colleagues Eva J. Gordon and William J. Sanders, dubbed "neoglycopolymers," also cause cells to shed the surface protein L-selectin and that prevents the cells from docking with each other.

"It's a completely different strategy," said Kiessling. "It's like doing surgery on a really small part of the cell's surface. We're removing a protein that facilitates an unwanted inflammatory response. One advantage of this strategy is that it's not reversible, so cells no longer adhere."

The neoglycopolymers work by causing the L-selectin proteins to bunch up on the cell's surface. This activates an enzyme within the cell that, like a chemical scissors, snips the L-selectin proteins from the cell surface.

When L-selectin is lost from the cell surface, the cell's docking mechanism is no longer available, and the sheared L-selectin proteins are turned loose in the bloodstream. There, the shed protein can attach themselves to the L-selectin-binding proteins on other cells, thereby acting as inhibitors to deter the inflammation response.

Does this mean an end to pain? No, said Kiessling, but the new agents suggest new ways to design far more effective tools than those now deployed in the multi-billion-dollar fight against inflammation.

Kiessling's group is now investigating whether this novel approach to removing L-selectin has potential implications for controlling other problematic proteins on the cell surface.

"We're trying to see how general the approach is and we're trying to find the enzyme that cuts L-selectin from the cell so that we can understand more about the process.

The work of Kiessling's group was funded by the National Institutes of Health and the Mizutani Glycoscience Foundation.


Story Source:

The above story is based on materials provided by University Of Wisconsin-Madison. Note: Materials may be edited for content and length.


Cite This Page:

University Of Wisconsin-Madison. "Snipping Inflammation In The Bud; New Agents May Provide Relief." ScienceDaily. ScienceDaily, 5 March 1998. <www.sciencedaily.com/releases/1998/03/980305053909.htm>.
University Of Wisconsin-Madison. (1998, March 5). Snipping Inflammation In The Bud; New Agents May Provide Relief. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/1998/03/980305053909.htm
University Of Wisconsin-Madison. "Snipping Inflammation In The Bud; New Agents May Provide Relief." ScienceDaily. www.sciencedaily.com/releases/1998/03/980305053909.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Cases Keep Coming for Monrovia's Island Hospital

Ebola Cases Keep Coming for Monrovia's Island Hospital

AFP (Oct. 1, 2014) A look inside Monrovia's Island Hospital, a key treatment centre in the fight against Ebola in Liberia's capital city. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Ebola Puts Stress on Liberian Health Workers

Ebola Puts Stress on Liberian Health Workers

AP (Oct. 1, 2014) The Ebola outbreak is putting stress on first responders in Liberia. Ambulance drivers say they are struggling with chronic shortages of safety equipment and patients who don't want to go to the hospital. (Oct. 1) Video provided by AP
Powered by NewsLook.com
Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Newsy (Sep. 30, 2014) After the announcement that the first U.S. patient had been diagnosed with Ebola, doctors were quick to say a U.S. outbreak is highly unlikely. Video provided by Newsy
Powered by NewsLook.com
TX Hospital Confirms Patient Admitted With Ebola

TX Hospital Confirms Patient Admitted With Ebola

AP (Sep. 30, 2014) Medical officials from Texas Health Presbyterian Hospital confirm they are treating a patient with the Ebola virus, the first case found in the US. (Sept. 30 Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins